<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146438">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093286</url>
  </required_header>
  <id_info>
    <org_study_id>PMS Penta 0414</org_study_id>
    <nct_id>NCT02093286</nct_id>
  </id_info>
  <brief_title>Safety Profile Following Pentabio Vaccination in Indonesian Infants</brief_title>
  <official_title>Phase IV, Study of Safety Profile Following Pentabio Vaccination in Indonesian Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <authority>Indonesia: National Agency of Drug and Food Control</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess any serious systemic reaction within 30 minutes after Pentabio immunization
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Any local and systemic reaction after Pentabio immunization
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Any serious adverse event occurring from inclusion until 30 minutes after the injection</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>local and systemic reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of local and systemic events occurring within 72 hours after each injection</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>any local and systemics events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of local and systemic events occurring from 72 hours up to 28 days following injection.</measure>
    <time_frame>25 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>any local and systemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of serious adverse events within 28 days after injection</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any serious adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pentabio Vaccine</arm_group_label>
    <description>1 dose of Pentabio vaccine, 0.5 ml Will be given intramuscularly</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        4000 infants, 2-11 months old From 4 provincial health primary center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Immunization with Pentabio vaccine

          -  Parents already understood the consequences to be involved in this study and having
             signed the informed consent form

          -  Parents agree and willing to fill in the Diary Card, to record all the reactions
             after immunization

        Exclusion Criteria:

          -  Given simultaneously with other vaccines or with the interval less than 1 month with
             other vaccination except OPV/IPV.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julitasari Sundoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AEFI National Committee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julitasari Sundoro, MD</last_name>
    <phone>+62811142047</phone>
  </overall_contact>
  <location>
    <facility>
      <name>West Java Provincial Ministry of Health</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kusnandi Rusmil, MD</last_name>
      <phone>+62811232774</phone>
    </contact>
    <investigator>
      <last_name>Kusnandi Rusmil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Nusa Tenggara Provincial Ministry of Health</name>
      <address>
        <city>Mataram</city>
        <state>West Nusa Tenggara</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>IGG Djelantik, MD</last_name>
      <phone>+628175795997</phone>
    </contact>
    <investigator>
      <last_name>I.G.G Djelantik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bali Provincial Ministry of Health</name>
      <address>
        <city>Bali</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I Made Gede Dwi Lingga, MD</last_name>
      <phone>+6281353002002</phone>
    </contact>
    <investigator>
      <last_name>I Made Gede Dwi Lingga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yogyakarta Provincial Ministry of Health</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mei Neni, MD</last_name>
      <phone>+628122961115</phone>
    </contact>
    <investigator>
      <last_name>Mei Neni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pentabio Vaccine</keyword>
  <keyword>Safety</keyword>
  <keyword>Infants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
